Holen Sie sich die Stockscreener-App
24.80
0.16%
0.04
Handel nachbörslich:
24.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
9 Analysts Have This To Say About Ultragenyx Pharmaceutical - Benzinga
Biopharma bites: Updated data for Ultragenyx's gene therapy, AI newco's $13.5M seed round, plus more from NMD, Vertex - FirstWord Pharma
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx Under Investigation After 87.64% Stock Drop Following Phase 3 Study Results - Intellectia AI
Howard Horn Sells 3,061 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE - Chartmill
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder - Benzinga
Ultragenyx (RARE) CFO Horn sells $72k in stock By Investing.com - Investing.com South Africa
Ultragenyx (RARE) CFO Horn sells $72k in stock - Investing.com
Ultragenyx Pharmaceutical Inc. Announces Long-Term Clinical Data Show Durable Benefits and Favorable Safety for UX111 Gene Therapy - marketscreener.com
HC Wainwright Reaffirms "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat
Ultragenyx Highlights New UX111 Data in FDA Resubmission - TipRanks
Ultragenyx (RARE) Reveals Promising Long-Term Results for Gene T - GuruFocus
RARE: HC Wainwright & Co. Reiterates Buy Rating with $60 Target - GuruFocus
Ultragenyx Pharmaceutical Reports Positive UX111 Study Results - TradingView
Ultragenyx Pharmaceutical Inc. Reports Promising Long-Term Results for UX111 Gene Therapy in Sanfilippo Syndrome Type A and Resubmits BLA to FDA - Quiver Quantitative
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Do - GlobeNewswire
Ultragenyx Pharma stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome - Finviz
Federated Hermes Inc. Trims Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Why Ultragenyx shares fell despite resubmitting its gene therapy? | Tap to know more | Inshorts - Inshorts
Ultragenyx resubmits BLA for Sanfilippo syndrome gene therapy By Investing.com - Investing.com South Africa
Novato's Ultragenyx tries — again — to convince FDA to approve brain disease gene therapy - The Business Journals
Rare stock slips 3% today — what’s up with Ultragenyx’s gene therapy for Sanfilippo syndrome? - MSN
Ultragenyx resubmits gene therapy for rare neuro disease to FDA - Endpoints News
Ultragenyx (RARE) Seeks FDA Approval for Gene Therapy UX111 - GuruFocus
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review - TipRanks
Ultragenyx resubmits BLA for Sanfilippo syndrome gene therapy - Investing.com
Ultragenyx Resubmits FDA Application for Potential Therapy for Rare Neurodegeneration Disease - marketscreener.com
Ultragenyx Pharmaceutical Resubmits BLA For UX111 AAV9 Gene Therapy - Nasdaq
Ultragenyx Resubmits BLA for UX111 Gene Therapy - TradingView
FDA to review resubmitted gene therapy for fatal Sanfilippo syndrome - Stock Titan
RARE Stock Slips 3% Today — What’s Up With Ultragenyx’s Gene Therapy For Sanfilippo Syndrome? - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Barclays reiterates Overweight rating on Ultragenyx Pharma stock By Investing.com - Investing.com Canada
Barclays reiterates Overweight rating on Ultragenyx Pharma stock - Investing.com
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a 163% Potential Upside Amidst Promising Rare Disease Treatments - DirectorsTalk Interviews
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today - AOL.com
Precision Trading with Ultragenyx Pharmaceutical Inc. (RARE) Risk Zones - Stock Traders Daily
Ultragenyx Pharmaceutical's Phase III Study Fails to Meet Primary Endpoint, Analysts Cut Price Targets - Intellectia AI
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies - Sahm
Ultragenyx Pharmaceutical (RARE) Valuation Check As 2025 Revenue Guidance Signals Stronger Growth - Sahm
Ultragenyx Pharmaceutical Inc. Faces Setback as Phase III Studies Fail to Meet Primary Endpoint - Intellectia AI
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Emerald Mutual Fund Advisers Trust Sells 52,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bone drug lifts density but not fractures, drawing Ultragenyx investor scrutiny - Stock Titan
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline - Seeking Alpha
Ultragenyx (RARE) Lifts 2025 Revenue Guidance, But What Does It Reveal About Growth Visibility? - Sahm
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring the 184% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Campbell & CO Investment Adviser LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Lobbying Update: $60,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
2026-01-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | NDAQ:RARE | Press Release - Stockhouse
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
1.22%
2.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):